Month: July 2022

In accordance with Article 33 (11) of the Republic of Lithuania Law on Companies, on 1 July 2022, the member of the Board of EPSO-G Ramūnas Abazorius, has declared his resignation from the position of the member of the Board of EPSO-G due to professional and investment activities, starting from 16 July 2022 (the last day as a member of the Board being 15 July 2022).

Introduces Four New (Lite) Ranch Wraps League City, Texas, July 01, 2022 (GLOBE NEWSWIRE) — Muscle Maker Grill, Muscle Maker, Inc.’s (Nasdaq: GRIL) “healthier for you” protein-based restaurant concept, which promotes a healthy lifestyle by offering nutritious alternatives to traditional dishes today announced the rollout of its new (lite) “Ranch It Up” Wraps menu which includes four (lite) ranch-based wraps. Muscle Maker Grill’s new (lite) “Ranch It Up” Wraps menu is a great option for those looking to indulge in a ranch-based wrap without the guilt. On par with its mission of delivering healthier menu items without sacrificing flavor, Muscle Maker Grill’s new (lite) “Ranch It Up” Wraps offers different builds to satisfy anyone’s ranch dressing craving! All (lite) “Ranch It Up” Wraps are served with a choice of a side and can...

HENDERSON, NV, July 01, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Grove, Inc. (NASDAQ:GRVI) (“Grove” or the “Company”), today announced that it has completed a strategic debt investment to fund future growth. Under the terms of the loan, the Company, at the initial closing, drew $7.5 million of the $15 million available. The Company could draw down against the remainder should it be needed to fund further profitable acquisitions in the future. The loan amortizes over 30 months and bears interest at a rate of 13% per annum, 8.5% payable in cash on the first day of each month hereafter and 3.5% PIK payable each month in arrears. There are fees, financial covenants, and prepayment fees associated with the loan, as well as a security agreement and other related agreements. As part of the terms of the loan,...

Incap Corporation                  Press release                1 July 2022 at 3:30 p.m. EESTThe corrected release includes the time of the webcast. Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company’s website at https://incapcorp.com/reports-and-presentations/. WebcastThe company will hold a webcast on Thursday, 28 July 2022 at 2:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap’s UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report....

Eventer will leverage its capabilities in the sports sector and intends to expand its outreach to leagues in the US and Europe Tel Aviv, Israel, July 01, 2022 (GLOBE NEWSWIRE) —  Medigus Ltd. (Nasdaq: MDGS) (“Medigus”), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that Eventer Technologies Ltd. (“Eventer”), a software company operating events and virtual events sector, 47.69% owned by Medigus, signed agreements with two basketball teams from the Israeli Basketball Premier League and the Israeli National Basketball League. As part of the agreements, Eventer will sell tickets for the teams’ games. Eventer has recently expanded its presence in the entertainment field by offering its services to teams and...

Biomea to present two oral abstracts across multiple animal models highlighting the ability of BMF-219, a covalent menin inhibitor, to significantly lower HbA1C (approximately two-fold greater reduction than active control, liraglutide) and to increase beta cell function. BMF-219 showed prolonged glycemic control in two standard diabetes animal models, the Zucker Diabetic Fatty (ZDF) and Streptozotocin-induced (STZ) Rat models, throughout the dosing period and, additionally, glycemic control was maintained after the dosing period ended. Oral Presentations to include additional data not released in the two posters presented at the American Diabetes Association Scientific Sessions on June 4, 2022. Biomea expects to initiate a Phase I/II clinical trial of BMF-219 in type 2 diabetes in the second half of 2022, subject to IND submission and...